Protembis develops the ProtEmbo Cerebral Protection System, an intra-aortic filter delivered via the left radial artery to deflect embolic material away from cerebral arteries during transcatheter aortic valve replacement (TAVR) and other left-sided heart procedures. The company is advancing ProtEmbo through clinical investigations, including a pivotal FDA‑approved Investigational Device Exemption (IDE) study intended to enroll 250–500 patients in Europe and the US. Protembis is using recent financing to support clinical trials, research and development, and market access for the next‑generation device. Financially, the company completed a €30 million Series B in March 2024 and has secured an additional €20 million venture‑debt facility from the European Investment Bank. The EIB financing is supported by the InvestEU programme and is intended to accelerate product development and regulatory pathways. Protembis is a privately held emerging medtech based in Aachen, Germany. Protembis has developed the ProtEmbo® Cerebral Protection System, an intra-aortic filter device designed to protect the entire brain from embolic material liberated during transcatheter aortic valve replacement (TAVR). The low-profile, non-thrombogenic system shields all cerebral vessels and is delivered via the left radial artery to avoid interference with femoral-delivered TAVR equipment. The ProtEmbo System is currently undergoing clinical investigations, including the PROTEMBO IDE Pivotal Trial (NCT05873816). Protembis says its technology aims to reduce brain injury during left-sided heart procedures, improve patient quality of life, and lower healthcare costs associated with such injuries. The company is privately held and headquartered in Aachen, Germany. Recent financing activity is intended to support the ongoing pivotal trial and pre-commercial programs. Protembis has developed the ProtEmbo, a catheter-based filter advanced via the radial artery to cover arteries leading to the brain while allowing blood cells to pass and blocking embolic particles; the filter is heparin-coated to reduce clotting. The device is designed to minimize particle migration to the brain during transcatheter aortic valve implantation (TAVI/TAVR) and other interventional heart procedures. Protembis reported initial safety and feasibility and demonstrated effectiveness in a first-in-human clinical study. The company plans further clinical studies at leading heart centers in Europe and the U.S. and aims to bring the ProtEmbo to market maturity. Protembis emphasizes a large and growing market opportunity driven by demographic trends and increased use of minimally invasive heart valve interventions. The company has closed institutional backing via a recent Series A to fund development toward commercialization.

Total raised

$64M

Funding rounds

3

Latest round

Debt Financing

Latest activity

Jul 2024